Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by longrun86on Nov 11, 2022 5:56pm
148 Views
Post# 35092817

RE:RE:Impacted by end of agrements in LATAM- is this only Gilead ?

RE:RE:Impacted by end of agrements in LATAM- is this only Gilead ?I think we can agree that it wasn't exactly the result we had hoped for. I am still optimistic for the platform in the long term.

The GBT acquisition is still being worked out and the return profile has a ways to go yet before it reaches an acceptable level of return. My take is that Management has forgone short term returns to focus on building a stronger foundation for the business.

The shares are cheap for those who are looking a little deeper but it still requires a faith in Managements ability to progress the platform and generate sufficient returns on the capital deployed. The NCIB has been a useful tool for creating value but I am approaching the point where I would be happy with them to execute on some opportunities that are more strategic.

LR


<< Previous
Bullboard Posts
Next >>